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Background: Most cases of rubella and congenital rubella syndrome (CRS) occur in low- and middle-income
countries. The World Health Organization (WHO) has recently recommended that countries accelerate the uptake of
rubella vaccination and the GAVI Alliance is now supporting large scale measles-rubella vaccination campaigns. We
performed a review of health economic evaluations of rubella and CRS to identify gaps in the evidence base and
suggest possible areas of future research to support the planned global expansion of rubella vaccination and efforts
towards potential rubella elimination and eradication.
Methods: We performed a systematic search of on-line databases and identified articles published between 1970
and 2012 on costs of rubella and CRS treatment and the costs, cost-effectiveness or cost-benefit of rubella
vaccination. We reviewed the studies and categorized them by the income level of the countries in which they
were performed, study design, and research question answered. We analyzed their methodology, data sources, and
other details. We used these data to identify gaps in the evidence and to suggest possible future areas of scientific
study.
Results: We identified 27 studies: 11 cost analyses, 11 cost-benefit analyses, 4 cost-effectiveness analyses, and 1
cost-utility analysis. Of these, 20 studies were conducted in high-income countries, 5 in upper-middle income
countries and two in lower-middle income countries. We did not find any studies conducted in low-income
countries. CRS was estimated to cost (in 2012 US$) between $4,200 and $57,000 per case annually in
middle-income countries and up to $140,000 over a lifetime in high-income countries. Rubella vaccination
programs, including the vaccination of health workers, children, and women had favorable cost-effectiveness,
cost-utility, or cost-benefit ratios in high- and middle-income countries.
Conclusions: Treatment of CRS is costly and rubella vaccination programs are highly cost-effective. However, in
order for research to support the global expansion of rubella vaccination and the drive towards rubella elimination
and eradication, additional studies are required in low-income countries, to tackle methodological limitations, and
to determine the most cost-effective programmatic strategies for increased rubella vaccine coverage.Background
Acquired rubella is a mild disease which only rarely re-
sults in serious clinical complications i.e. encephalitis,
arthritis and thrombocytopenia. The mild nature of the
disease means that vaccination against it would not be
medically or economically critical or justifiable if it did
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distribution, and reproduction in any mediumticularly in the first trimester, rubella infection is far
more dangerous and commonly leads to abortion, fetal
death or congenital rubella syndrome (CRS) [1]. CRS,
which is estimated to affect 110,000 infants annually in
low-income countries [2], is characterized by multiple
defects of the brain, heart, eyes and ears and is an im-
portant cause of hearing and visual impairment and
mental retardation. CRS often causes lifelong physical
and mental disability, requiring costly institutional care
and special schools, and using a large amount of
healthcare and societal resources. Therefore CRS pro-
vides the medical and economic rationale for appropri-
ate prophylaxis with a vaccine.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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available for over 40 years. It has a high immunogenicity,
produces sero-conversion in close to 100% of vaccines,
and confers immunity similar to that of natural infection
[1]. Immunity is maintained for at least 20 years and
although infection, including CRS, may occur in vacci-
nated individuals with low antibody titers, this is not an
important factor in rubella epidemiology [1]. The rubella
vaccine is available in combination with measles (MR)
and with measles and mumps (MMR) as well as in
monovalent form (R). Combination with other vaccines
does not affect immunogenicity [1].
Most high- and middle-income countries include rubella-
containing vaccine (RCV) in their childhood immunization
schedules and have made progress in reducing the inci-
dence of rubella or eliminating it. The World Health
Organization (WHO) Latin American region (AMR) has
eliminated rubella and CRS [3] and the European region
(EUR) registered a 98% reduction in cases between 2000
and 2009 [4].
Although WHO published a position paper to guide
introduction of RCV into the national childhood
immunization schedules of member countries in 2000
[5], only a few low-income countries have included the
vaccine in their schedules [4]. This is reflected in the
epidemiological trends: the WHO eastern Mediterranean
region (EMR) registered only a 35% reduction in rubella
cases between 2000 and 2009 and the WHO African re-
gion (AFR) and South East Asian region (SEAR) regis-
tered 20-fold and 14-fold increases in rubella cases
respectively during the same time period [4]. Of the 165
reported cases of CRS in 2009, AFR, with 47, had the
highest number [4].
Low-income countries have been slow to add RCV to
their national immunization schedules because of several
reasons, two of which stand out. First, despite its relatively
low price (as might be supplied to UNICEF or through a
GAVI Alliance subsidy), adding rubella to the vaccine
schedule might be prohibitively costly in countries where
healthcare budgets are already stretched. This suggests
that including RCV in immunization schedules in poor
countries is not cost-effective compared to other public
health interventions. Second, because rubella causes a
substantial proportion of its damage in fetuses, a high level
of vaccination coverage (over 80%) must be maintained to
avoid the risk of increasing the incidence of CRS which
would happen if poor vaccine coverage reduced viral cir-
culation in the population enough to shift rubella suscepti-
bility from children to young mothers. This creates a
unique policy problem: including RCV in national
immunization schedules is likely not enough; the rubella
immunization programs need to achieve herd immunity
and many countries are unable to feasibly sustain such
coverage standards.A more recent position paper by WHO recommended
that countries leverage accelerated measles control and
elimination activities to introduce RCV and exploit this
synergy to advance rubella and CRS elimination [6]. In
line with the WHO recommendation, the GAVI Alliance
is supporting large-scale catch up measles-rubella cam-
paigns with the aim of reaching over 700 million chil-
dren in 49 countries by 2020 [7].
Health economics, the study of how scarce healthcare
resources are deployed and should be allocated in
healthcare systems, has gained increasing prominence
globally in the face of slowing western economies and
continued resource constraints in low-income countries.
Donors are increasingly scrutinizing the use of resources to
assist poor countries in fighting disease and governments
in low-income countries are increasingly scrutinizing their
healthcare expenditures. Economic evaluations help policy
makers to make resource allocation decisions by identify-
ing different policy strategies, transparently evaluating their
costs and benefits, quantifying the uncertainty around esti-
mates, and examining different scenarios.
In 2002, Hinman et al. performed a global review of
economic analyses of rubella and rubella vaccines pub-
lished between 1970 and 2000 [8]. They found that in-
clusion of rubella vaccination in national immunization
programs is both cost-beneficial and cost-effective and
recommended further studies using data from the bur-
den of rubella in developing countries and standardized
methodologies [8].
In this paper, we present findings of an updated review
of economic analyses of rubella and rubella vaccination.
We examine the evidence on costs of rubella and CRS, the
cost-effectiveness of adding RCV to national immunization
programs, and the cost-effectiveness of different policy
strategies that might be employed to add RCV to national
childhood immunization schedules. Our aim is to examine
the economic evidence base, assess differences in findings
by country income levels, identify gaps in the evidence,
and propose potential areas of future enquiry into the eco-
nomics of rubella and rubella vaccination. Our findings will
support the planned global expansion of RCV and the push
towards potential rubella elimination and eradication.
Methods
We reviewed studies published in English on the costs
and resource use for rubella and CRS and the costs, cost-
effectiveness or cost-benefit of rubella vaccination between
1970 and 2012. This review is up-to-date as of December
1st 2012 and conforms to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [9].
We performed a systematic search of MEDLINE
(PubMed) and the National Health Services Economic
Evaluation Database. Our search strategy included the
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costs’, ‘rubella and cost-effectiveness’, ‘rubella and cost-
utility’, ‘rubella and cost-benefit’, ‘CRS and economics’,
and ‘CRS and costs’. The search limits were set to the
custom range of dates as described above. The studies
identified were reviewed one-by-one by reading their ab-
stracts and identifying the design of the study as
reported. The review included health economic evalua-
tions i.e. cost analyses, cost-effectiveness analyses, cost-
utility analyses, cost-benefit analyses, cost-consequences
analyses, and cost-minimization analyses. The economic
evaluation studies were further reviewed to identify any
references that did not show up in the initial search.
After reviewing the studies chosen, we categorized
them by study design and income level of countries in
which they were performed. We used the World Bank
definition, which categorizes countries according to Gross
National Income (GNI) per capita in 2011 as follows: low
income, $1,025 or less; lower middle income, $1,026 -
$4,035; upper middle income, $4,036 - $12,475; and high
income, $12,476 or more [10]. For the cost-effectiveness
and cost-utility analyses, we used the 16-item Quality of
Health Economics Studies (QHES) questionnaire [11] to
assess study quality. This validated instrument can be used
to quickly and accurately measure aspects of the quality of
health economics studies on a scale of 0 – 100 and has
been used to identify evidence to enhance decision making
[12]. A higher score on the QHES indicates a study of bet-
ter quality. We used the results to identify potential gaps
in the evidence on the economics of CRS and rubella
vaccination as it relates to the planned expansion of RCV
and the potential for the global interruption of rubella
transmission.Results
Our initial search identified 976 studies whose abstracts
were reviewed and we selected 27 relevant studies on
the economics of rubella, CRS, and rubella vaccination:
11 cost analyses, 11 cost-benefit analyses, 4 cost-
effectiveness analyses, and 1 cost-utility analysis.
We included studies of the costs of CRS, cost analyses
comparing strategies to screen healthcare workers and
identify candidates for immunization, cost analyses com-
paring vaccination programs, and full economic evalua-
tions of healthcare programs.Study design
Of the 11 cost analyses selected, 4 examined the costs of
CRS [13-16], 4 compared the costs of blind and targeted
vaccination of health care workers [17-20], 1 compared the
costs of fully immunizing a child using different vaccines
[21], 1 compared different approaches to vaccinating chil-
dren, adolescent girls, and women [22], and one compareddifferent strategies for testing pregnant women followed by
immunization of susceptible women after birth [23].
All 11 cost-benefit analyses [24-34] compared different
programmatic approaches to vaccination in the general
population targeting children, girls, or women and 2 of the
studies evaluated programs aimed at rubella eradication.
All 4 cost-effectiveness analyses [35-38] and the single
cost-utility analysis [39] compared different program-
matic approaches to vaccination in the general popula-
tion and 1 study evaluated a program aimed at rubella
eradication [36]. Of the 5 cost-effectiveness and cost-utility
analyses, we had enough information to score 3 studies;
one study was based on summary results in a report [36]
and the other was reported in Slovak [37]. The three studies
scored 30 [35], 62 [39] and 93 [38] on the QHES (on a scale
of 0 – 100).
Twenty studies were conducted in high-income coun-
tries, 5 in upper-middle-income countries and two in
lower-middle-income countries. We did not find any
studies conducted in low-income countries.
Cost analyses
Studies of the costs of congenital rubella syndrome (CRS)
All costs were converted to 2012 US dollars for com-
parison using historical consumer price indices for all
countries based on data from the International Monetary
Fund [40]. Table 1 is a summary of the four published
studies of the cost of congenital rubella syndrome (CRS),
three of which were from upper-middle-income countries.
Three studies [14-16] evaluated the annual direct costs of
treatment of CRS (hospitalization, outpatient visits, diag-
nostic tests, surgery, drugs and equipment) which ranged
from (2012) $4,261 in Brazil [14] to (2012) $57,010 in
Jamaica [16]. Differences were found among the studies
with regard to the goods and services that were included
in the cost analyses, e.g., some studies included the costs
of surgery and cochlear implants while others did not
(Table 1). The fourth study [13] estimated the lifetime dir-
ect costs of treatment and indirect productivity losses due
to CRS in Oman to be (2012) $139,910.
Cost analyses of vaccination programs for health care
workers
Healthcare workers without a history of acquired rubella
are susceptible to infection in health facilities. Screening
detects rubella antibodies in serum using serological
tests and screening programs are designed to identify in-
dividuals without antibodies, who are candidates for
immunization. Analysts have compared the costs of dif-
ferent strategies to identify and immunize susceptible
health workers. Table 2 is a summary of the four pub-
lished cost analyses that evaluated the costs of providing
rubella containing vaccines to health care workers. Two
strategies were compared: vaccinating all health care
Table 1 Studies of the cost of congenital rubella syndrome
First author [Reference] de Owens [15] Robinson [16] Lanzieri [14] Al-Awaidy [13]
Country Panama Jamaica Brazil Oman
Year 1989 1998 2004 2006
WB income group Upper middle Upper middle Upper middle High





NR NR Diagnosis; OP care;
Hospitalization Surgery; 1st
year of FU
Diagnosis; OP care; Hospitalization Surgery; Drugs;
Equipment; Special schools; Indirect costs
Method of cost
estimation
NR NR Micro-costing using
reimbursement data
Micro-costing using accounts data (treatment
costs); Human capital approach (for indirect costs)
Time period for costing Annual Annual Annual (1st year) Lifetime
Discounting (Rate) NA NA NA Yes (3%)
Results (2012 US$) $58,023 $57,010 $4,261 $139,910
Sponsor NR NR NR Oman MOH*
*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; OP, Out-Patient; FU, Follow-Up; CRS, Congenital Rubella Syndrome; MOH, Ministry of Health.
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only the health workers whose tests were negative for
rubella antibodies. Two of the studies took place in high-
income countries [17,18] while the other two [19,20] were
performed in Turkey, an upper- middle-income country.Table 2 Cost analyses of vaccination programs for healthcare
First author [Reference] Stover [17] Ferson [18]
Country USA Australia
Year 1994 1994
WB income group High High
Comparators 1. Screen & vaccinate 1. Vaccinate all
2. Blind vaccination 2. Vaccinate if no d
3. Test if no disease
vaccinate











Time period for costing One-time vaccination One-time vaccinati
Discounting (Rate) NA NA
Results (2012 US$) 1. $24 1. $5 – $37
2. $71 2. $5 – $28
3. $5 – $28
4. $9 - $42
Stated conclusion Screen and vaccinate
preferable
A combination if sc
preferable
Sponsor NR NR
*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; TSRC, Turkish Science ReseaThe two studies in high-income countries found that the
costs of screening and vaccinating were lower and that this
was preferable to blind vaccination, although Ferson et al.
[18] found that blind vaccination might be preferable
when conditions made testing an administrative burden.workers
Celikbas [19] Alp [20]
Turkey Turkey
2006 2012
Upper middle Upper middle
1. Screen & vaccinate 1. Screen &
vaccinate






Vaccine; serology Vaccine; serology
Micro-costing Micro-costing
on One-time vaccination One-time
vaccination
NA NA
1. $14 1. $13
2. $18 2. $9






Babigumira et al. BMC Public Health 2013, 13:406 Page 5 of 12
http://www.biomedcentral.com/1471-2458/13/406The findings of the two studies from Turkey were mixed:
one [19] found that the costs of blind vaccination were
slightly higher than targeting and the other [20] found that
blind vaccination was less costly.
Cost analyses of rubella vaccination programs
Three analyses from high-income countries evaluated
the costs of various strategies to introduce rubella vac-
cine (Table 3). Gudnadottir [22] compared four strategic
programmatic approaches in Iceland to preventing CRS by
routine immunization using the monovalent Rubella RA27/
3 vaccine: 1) the United States program at the time (vaccin-
ation of all children to create herd immunity and later
(when CRS did not disappear), revaccinating all young adult
women); 2) the United Kingdom program at the time (vac-
cination of teenage girls and sero-negative women (plus
contraception for three months after vaccination)); 3) the
Sweden program at the time (vaccination in early childhood
and re-vaccination of all teenagers (general re-vaccination))
and 4) selective vaccination involving puerperal women as






WB income group High High
Group targeted Children Children
Comparators 1. Vaccinate all children and re-vaccinate
women
1. MMR va
2. Vaccinate girls and sero-negative women 2. DTaP va
3. Vaccinate all children and re-vaccinate
girls
3. IPV vacc










One-time vaccination at different ages One-time v
number of
Discounting (Rate) NA NA
Results (2012 US$) 1. $1,063 1. $30
2. $638 2. $23
3. $2,409 3. $18
4. $283




Sponsor Iceland MOHSS US CDC
*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; MOHSS, Ministry of Health a
Rubella; IPV, Inactivated Polio Vaccine; CDC, Centers for Disease Control; NMBS, Navuse contraceptives for three months. The study found that
systematic screening of women and teenage girls combined
with vaccination of sero-negative individuals was the most
cost-effective strategy for reduction of CRS in Iceland,
followed by vaccination of 12 – 13 year old school girls.
Fontanesi et al. [21] compared the costs of fully immun-
izing a child using MMR, diphtheria–tetanus–attenuated
pertussis (DTaP) vaccine, and the inactivated polio vaccine
(IPV) in the US. They estimated that the average cost of
providing a single MMR vaccination (in 2012 US $) was
US$30 compared to $23 for DTaP and $18 for IPV. Haas
et al. [23] compared various strategies for vaccination of
pregnant women: 1) rubella testing and rubella vaccin-
ation, 2) rubella testing and MMR vaccination, 3) MMR
testing and MMR vaccination, and 4) MMR testing and
rubella only or MMR vaccination. As expected, it was less
costly to screen for rubella than for MMR.
Cost-benefit analyses of rubella vaccination programs
Tables 4, 5, and 6 present summaries of the eleven cost-






ccination 1. Rubella test and rubella vaccine
ccination 2. Rubella test and MMR vaccine
ination 3. MMR test and MMR vaccine
4. MMR test and rubella/MMR vaccine
Payer*










vaccine had the highest cost
ized child
The combined MMR test and vaccination
was the most costly
NMBS
nd Social Services; MMR, Measles Mumps Rubella; DTaP, Diptheria Mumps
y Bureau of Medicine and Surgery.
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the other (Irons et al. [34]) was performed in a number
of upper-middle-income countries. The studies com-
pared the costs and benefits of 1) vaccinating with MMR
vs. monovalent rubella vaccine, 2) vaccinating various
age groups vs. no program, 3) introducing a second dose
of MMR, and 4) rubella elimination.
Four studies [26,27,30,31] compared MMR with
monovalent rubella vaccine. All but the study performed
in 1979 in Finland [31] found that vaccination with
MMR is preferable. White et al. [26] performed a cost-
benefit analysis of a routine childhood MMR vaccine
program in the US compared to no vaccination, or vac-
cination with individual (measles, mumps or rubella) an-
tigens and found that the MMR vaccine had a higher
benefit to cost ratio than the monovalent ones andTable 4 Cost-benefit analyses of vaccination programs in the
First author [Reference] Stray-Pedersen [25] White [26]
Country Norway USA
Year 1982 1985
WB income group High High
Comparators 1. Vaccinate infant girls 1. Rubella vaccinati




























Averted costs Averted costs
Time period for costs and
benefits
Lifetime Lifetime
Discounting (Rate) Yes (7%) Yes (10%)
Results—Benefit-cost ratio 1. 5 1. 7.7
2. 11 2. 14.4





*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; CDC, US Centers for Diseasewould be preferred. Hatzandrieu and Halpern [27] repli-
cated the methods of White et al. [26] with similar
findings, that introducing MMR vaccine was more cost-
beneficial than monovalent rubella vaccine. Berger [30]
conducted an analysis in Israel of the costs and benefits
of introducing a mumps-rubella vaccine to monovalent
antigens and found that the combined vaccine was
preferable. Elo [31] on the other hand, found that vac-
cination with rubella vaccine in Finland was more cost-
beneficial.
Six studies compared immunization delivery strategies
targeting different age groups. Three studies, one in
Denmark [28] and two in Israel [30,32], found that it was
more cost-beneficial to vaccinate infants and pubertal
girls. One study [24] in the US found that it was better to
vaccinate 12 year old girls than two year old children. Thegeneral population




on 1. Rubella vaccination 1. Vaccinate all 2-yr-olds
2. MMR vaccination 2. Vaccinate all 6-yr-olds
















indirect costs (lost wages, lost









Micro-costing (for direct costs;






Averted costs Averted costs
Lifetime Lifetime
Yes (10%) Yes (6%)
1. 11.1 1. 8
2. 21.3 2. 9
3. 27
4. 8
ne program Routine MMR vaccine program
was cost-effective





Table 5 Cost-benefit analyses of vaccination programs in the general population
First author [Reference] Bjerregaard [28] Pelletier [29] Elo [31] Berger [30]
Country Denmark Canada Finland Israel
Year 1991 1998 1979 1990
WB income group High High High High
Comparators 1. Vaccinate 15-
month and 12-
yr-olds
1. 1-dose child vaccination campaign 1. Vaccinate 13-
yr-olds & post-
partum women
1. Vaccinate children from
1 – 12 years
2. Vaccinate only
15-month-olds
2. 2-dose child vaccination campaign 2. Vaccinate 13-yr
-olds & 1-yr-olds
2. Vaccinate only 12-yr-olds
(routine)
3. 1-dose child vaccination 3. Vaccinate only 1-
yr-olds over 20 years
4. 2-dose child vaccination







OP visits; hospitalizations; laboratory tests;
nursing home care; special education;
indirect costs (lost productivity for illness,



















Averted costs Averted costs Averted costs Averted costs
Time period for costs and
benefits
20 years Lifetime 30 years 13 years
Discounting (Rate) NR Yes (5%) Yes (6%) Yes (5 and 10%)
Results—Benefit-cost ratio 1. 3 1. 2.6 1. 10 1. 1.1
2. 2 2. 2.9 2. 3 2. 1.8
3. 3.6 3. 6
4. 4.3
Stated conclusion Vaccinating both
age groups is
preferable







adolescent girls is preferable
Sponsor NR LCDC NR NR
*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; OP, Out Patient; CDC, US Centers for Disease Control and Prevention; LCDC, Canada Laboratory Center for
Disease Control.
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cinate pubertal girls and postpartum women.
Two studies evaluated the costs and benefits of rubella
elimination. Kommu and Chase [33] estimated a benefit to
cost ratio of 4.7. Irons et al. (2000) [34] performed a cost-
benefit analysis of rubella elimination in the English-
speaking Caribbean. They estimated a disease burden of
1,500 cases in all the countries and an expenditure on CRS
of (2012) US$ 126 million. A campaign to interrupt rubella
transmission would cost (2012) US$9.1 million and result
in a benefit to cost ratio of 13.3 for a rubella and CRS eradi-
cation campaign involving mass vaccination in 18 countries.
Cost-effectiveness analyses of rubella vaccination programs
Table 7 is a summary of the five cost-effectiveness stud-
ies that evaluated rubella vaccination. Of these, fourwere conducted in high-income countries (one each in
France [35], Slovakia [37], the USA [38] and Netherlands
[39]) and the other was conducted in a lower-middle-in-
come country (Guyana) [36]. Three studies assessed the
cost-effectiveness of national rubella or MMR vaccination
[35,37,38], one study evaluated different approaches to
screening women to identify candidates for immunization
in the [39] and the other evaluated rubella elimination in
Guyana [36]. The three studies of national-level vaccin-
ation found that it would be cost-effective. In Hudeckova’s
study in Slovakia [37], the introduction of MMR vaccin-
ation yielded cost savings of (2012) $16 million) and a cost
per case prevented of (2012) $313. Zhou’s study found that
a two dose MMR program in the US would save (2012)
$231 per rubella case prevented and (2012) $683,813 per
CRS case prevented [38].
Table 6 Cost-benefit analyses of vaccination programs in the general population
First author [Reference] Golden [32] Kommu [33] Irons [34]
Country Israel Barbados Caribbean
Year 1984 1998 2000
WB income group High High Upper-middle
Comparators 1. Vaccinate all 1 - 12-yr-olds 1. Rubella elimination initiative 1. Initiative to interrupt rubella
transmission
2. Vaccinate pubertal girls 2. None 2. None
3. Vaccinate adult females
Perspective Societal* Payer* Payer*
Cost components
measured
Laboratory tests; abortions; primary care;







Averted costs NR NR
Time period for costs and
benefits
10 years 15 years 20 years
Discounting (Rate) Yes (10%) NR NR
Results—Benefit-cost ratio 1. 1 1. 4.7 1. 13.3
2. 2 2. – 2. –
3. Negative
Stated conclusion Vaccination of children and pubertal girls
is preferable
The rubella elimination program
using MMR was cost-beneficial
The rubella elimination program
using MMR was cost-beneficial
Sponsor NR NR NR
*Not explicitly reported but inferred.
WB, World Bank; NR, Not Reported; NA, Not Applicable; OP, Out Patient; CDC, US Centers for Disease Control and Prevention; LCDC, Canada Laboratory Center for
Disease Control.
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cination of susceptible women. They compared the
screening of non-vaccinated pregnant women in areas of
low-vaccine coverage, the screening of all pregnant
women in these areas, and the screening of all non-
vaccinated pregnant women throughout the country.
The study, which was performed from the perspective of
the healthcare system, found that screening non-
vaccinated women in areas with low vaccine coverage
and vaccinating the susceptible was the most cost-
effective with a cost/QALY of (2012) $2,300 compared
to screening all women in areas of low vaccine coverage
((2012) $62,000/QALY) and screening all women in the
country ((2012) $115,000/QALY).
Kandola [33] estimated that a rubella elimination cam-
paign in Guyana would cost (2012) $950,000. The long-
term financial savings would be US$ 36.9 million
(undiscounted) for a cost-effectiveness ratio of (2012)
$3,335 per CRS case prevented.
Discussion
This review of published economic analyses of rubella,
CRS, and rubella vaccination suggests some general
themes about economics of the disease and the value ofvaccination. In high- and middle-income countries, CRS
is such a costly disease that rubella vaccination is a high
value intervention.
The review revealed that a broad consensus over four
decades and in a variety of high- and middle-income
countries has existed, i.e., rubella vaccination (including
different programmatic approaches to vaccination) is
cost-effective or cost-beneficial. This has been true for
vaccination of children of both genders (to interrupt
rubella transmission) [24,25,28-33]; vaccination of teen-
age girls or adult women (to prevent CRS) [39,41]; and
vaccination of children, adolescent girls, or adult women
[22,24,25,28,30-32]. In general, vaccination to prevent
CRS was more cost-beneficial or cost-effective than vac-
cination to interrupt rubella transmission.
With regard to testing and vaccination of hospital
workers, earlier studies [17,18] suggested that blind vac-
cination was preferable to targeted vaccination (after
serological screening). But more recent studies found
that blind vaccination is only slightly more costly [20] or
less costly than targeted vaccination [19]. Cost analyses
also suggest that vaccination is affordable for health
workers, [17,18] among children [21] and among post-
partum women [23]. This finding suggests that as
Table 7 Cost-effectiveness and cost-utility analyses of vaccination programs in the general population




Zhou [38] Lugner [39]
Country France Guyana Slovakia USA Netherlands
Year 1978 1998 2001 2004 2010
WB income group High Upper-
middle
High High High








1. Rubella vaccination program 1. Screen and
vaccinate all
unvaccinated in LVR
2. No vaccination 2. No
campaign












obstetric care; intensive care
NR NR** Vaccination; OP care;
hospitalization; institutional care;
special care; Indirect (premature






Top-down costing NR NR** Micro-costing; Human capital
approach (indirect costs)
Micro-costing
Time period for costs and
benefits
15 years 5 years NR** 40 years 16 years
Discounting (Rate) Yes (NR) NR NR** Yes (3%) Yes (4%)




Cases prevented; lives saved QALYs
Method of outcome
measurement
Primary analysis of program
data










1 dominated 2; the
ICER comparing 3 to
1 was $114,575/QALY
gained
















is the most cost-
effective
QHES score 30 NS NS 93 62
Sponsor NR NR NR CDC NL CIDC
*Not explicitly reported but inferred **Article in Slovak.
WB, World Bank; NR, Not Reported; NS, Not Scored; OP, Out Patient; LVR, Low vaccination coverage regions; NL, Netherlands; CDC, US Centers for Disease Control
and Prevention; CIDC, Center for Infectious Disease Control; QALYs, Quality-Adjusted Life-Years.
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ation has become more favorable compared to targeted
vaccination.
The use of mass campaigns was modeled in Canada
[29] and the Caribbean [16,33,34,36] and in conjunction
with routine immunization. One study evaluated the use
of monovalent rubella vaccine [21] and another MR in
an evaluation of adding childhood immunization to an
already-existing program of immunizing 12-yr old girls
[30]. The others used MMR only, [26,28,32,37,38] MMR
and monovalent rubella vaccine [25,33,34,36] or MMR
for routine and MR for campaigns [29]. Both campaignsin conjunction with routine immunization and routine
programs, regardless of the vaccine presentation used,
were cost-beneficial.
One of the most striking findings was that no studies
have been performed in low-income countries where the
highest burden of rubella and CRS exists. This may be
due to the limited treatment options for CRS and use of
RCV in these countries. However, now that the GAVI
Alliance has introduced funding for RCV into its pro-
gram [7], demand for these analyses should increase.
Conducting economic analysis of introducing RCV in
low-income countries would provide useful information for
Babigumira et al. BMC Public Health 2013, 13:406 Page 10 of 12
http://www.biomedcentral.com/1471-2458/13/406program managers and policymakers on which service de-
livery strategies are cost-effective and cost-beneficial and
which age groups should be targeted. Economic analyses
on RCV will not be needed in every country before
RCV since studies from countries with similar socio-
demographic circumstances can be informative [42,43].
However, given the high cost of CRS and the low cost of
vaccination, as well as increasing price inflation of
healthcare and other services used in the care of disabled
children, that the net economic benefit of rubella vaccin-
ation will remain substantial in analyses in this setting [44].
Economic analyses of RCV should examine, for ex-
ample, whether efficiencies can be gained from using a
combination vaccine (MMR) compared to monovalent
vaccine [26]. Since measles vaccination is already part of
the routine immunization program in all low-income
countries [42], studies could assess the cost-effectiveness
of substituting MMR and MR for monovalent measles
vaccine. Plotkin [1] suggests that there will be a large
opportunity cost if measles immunization activities do
not take advantage of reducing rubella simultaneously
and that the cost-effectiveness of rubella vaccination in
low-income countries should be taken into account
within the context of measles control and elimination.
There are two ways of implementing new rubella vac-
cine initiatives in countries: vaccinating adolescent girls
and/or women of childbearing age to reduce CRS and
vaccinating children using combined measles and rubella
vaccines (MR or MMR) to interrupt rubella transmission
altogether [42,43]. It would be worthwhile to perform
economic analyses to determine which option should be
implemented in low-income countries. Three factors
make it likely that vaccination of teenage girls and
women of childbearing age will be more efficient in low-
income than in high-income countries: 1) later
immunization reduces the time to benefits because there
are fewer years to discount; 2) the costs of acute child-
hood rubella are so small that the net benefit of early
vaccination is diminished; and 3) since the vaccine pro-
vides immunity for at least twenty years, immunity
would increase among adults [44].
We also found some methodological issues related to
discounting. Studies differed as to whether or not
discounting was performed and which discount rate was
used. Discounting allows analysts to value current costs
more than future costs given the opportunity cost asso-
ciated with current relative to future expenditure [45]. It
is desirable to avert healthcare costs today because such
savings can be invested for a future return [45]. Many of
the older studies used discount rates as high as 5% [30]
or 10% [26,30] although these still found that vaccin-
ation was associated with net economic benefits. Future
studies should consider using lower discount rates since
the choice of discount rate and number of years ofdiscounting affects the potential cost-effectiveness of
childhood vaccination.
None of the economic studies reviewed considered herd
immunity or potential adverse outcomes associated with
vaccination. When herd immunity is taken into account, it
increases the attractiveness of mass vaccination campaigns
at the onset of programs and on-going vaccination of chil-
dren [44]. On the other hand, as mentioned earlier, if
rubella coverage is too low, RCV could increase the rubella
susceptibility of women. Future studies might consider
using dynamic modeling methods as the basis of economic
evaluations to capture the potential effects of coverage and
herd immunity.
Only one of the studies, a cost-effectiveness analysis
[39], included adjustments for disability. Because rubella
has potentially significant impacts on the quality of life
of CRS patients and their caretakers, future studies
might consider estimating the cost per DALY saved or
cost per QALY gained.
Rubella has both maternal and child health conse-
quences because maternal infection can cause abortion.
Some studies measured the costs of abortions [32] but
most did not. In low-income countries where the burden
of rubella and CRS are high and induced abortions are
illegal, many more babies with CRS may be born without
the option of therapeutic abortion and this would have
economic consequences. Moreover, models may need to
consider levels of fertility and induced abortion as they re-
late to CRS burden, as well as the economic consequences
of safe or unsafe abortions or abortions performed in re-
sponse to a diagnosis of CRS. Since vaccination may pre-
vent many medically-indicated abortions in developed
countries and clandestine abortions in developing coun-
tries, studies might quantify this potential economic and
health outcomes impact.
Conclusions
Congenital rubella syndrome is costly and rubella
vaccination programs, including the vaccination of
health workers, children, and women has favorable cost-
effectiveness, cost-utility, or cost-benefit ratios in high-
and middle-income countries.
However additional studies are required to include
low-income countries, tackle methodological limitations,
establish the efficiency of immunization programs in
conjunction with measles immunization, and establish
the most efficient rubella vaccination schedule.
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